Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial

Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial

Show other versions (1)

Background: Oesophageal adenocarcinoma (OA) is the sixth commonest cause of cancer death worldwide and Barrett’s oesophagus (BO) is the most significant risk factor. We evaluated the efficacy of high-dose esomeprazole proton pump inhibitor acid suppression (PPI) and aspirin in improving outcome for...

Full description

Bibliographic Details
Main Authors: Jankowski, J, de Caestecker, J, Love, S, Reilly, G, Watson, P, Sanders, S, Ang, Y, Morris, D, Bhandari, P, Attwood, S, Ragunath, K, Rameh, B, Fullarton, G, Tucker, A, Penman, I, Rodgers, C, Neale, J, Brooks, C, Wise, A, Jones, S, Church, N
Format: Journal article
Published: Elsevier 2018

Similar Items